ClinicalTrials.gov record
Recruiting Phase 2 Interventional

A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy

ClinicalTrials.gov ID: NCT06848231

Public ClinicalTrials.gov record NCT06848231. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 12:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind, Placebo-Controlled, Multi-Center, Phase II, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of YA-101 in Subjects With Multiple System Atrophy

Study identification

NCT ID
NCT06848231
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Dasher Neuroscience Inc.
Industry
Enrollment
75 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • YA-101 Drug

Drug

Eligibility (public fields only)

Age range
30 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 2, 2025
Primary completion
Jun 29, 2026
Completion
Dec 30, 2026
Last update posted
Apr 28, 2026

2025 – 2026

United States locations

U.S. sites
6
U.S. states
6
U.S. cities
6
Facility City State ZIP Site status
UCLA Health Los Angeles California 90095 Recruiting
Brigham and Women's Hospital Boston Massachusetts 02115 Recruiting
Mayo Clinic Rochester Minnesota 55905 Recruiting
Columbia University Irving medical center New York New York 10032 Recruiting
Vanderbilt University Medical Center Nashville Tennessee 37232 Recruiting
Baylor College of Medicine Houston Texas 77030 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06848231, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 28, 2026 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06848231 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →